|Poll|October 3, 2014

Mini-quiz: Reporting Child Abuse

Are psychiatrists mandated to report patient self-disclosures of child abuse in every case? The answer might surprise you.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe Now!

Related Content

adolescent psychiatry lifestyle medicine obesity

Youth Lifestyle Psychiatry: Addressing Obesity in the Psychiatric Setting

ByTiffani L. Bell Washington, MD, MPH, FAPA,Jessica Walters

November 26th 2025

New Drug Application Submitted for Centanafidine for Treatment of ADHD

ByJessica Walters

November 25th 2025

Tolerance to Stimulant Medications in the Treatment of Children With ADHD

ByJames M. Swanson, PhD,Anthony A. Grace, PhD

November 21st 2025

FDA Clears Deep Transcranial Magnetic Stimulation for Adolescents With MDD

ByLeah Kuntz

November 14th 2025

NCCHC 2025 Virtual Winter Conference on Correctional Health Care Offers CE and Remote Education on Critical Topics

ByKim Sterling

November 4th 2025

Latest CME

In-Person + Virtual Event

Real Psychiatry 2026

January 23-24, 2026

Video

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Michael Asbach, DMSc, PA-C; Erin Crown, MHS, PA-C, Psych-CAQ

Video

Optimizing Care for Patients With Tardive Dyskinesia

Amber Hoberg, MSN, APRN, PMHNP-BC; Erin Crown, PA-C, Psych-CAQ

Video

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Jonathan Meyer, MD; Jacob Hanaie, PharmD, APh, BCPP; Sanjai Rao, MD, DFAPA

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Mini-quiz: Reporting Child Abuse

Newsletter

Related Content

Youth Lifestyle Psychiatry: Addressing Obesity in the Psychiatric Setting

New Drug Application Submitted for Centanafidine for Treatment of ADHD

Tolerance to Stimulant Medications in the Treatment of Children With ADHD

FDA Clears Deep Transcranial Magnetic Stimulation for Adolescents With MDD

NCCHC 2025 Virtual Winter Conference on Correctional Health Care Offers CE and Remote Education on Critical Topics

Latest CME

Real Psychiatry 2026

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Optimizing Care for Patients With Tardive Dyskinesia

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

Psychedelic PSX-001 for Generalized Anxiety Disorder: A Conversation With Lou Barbato, MD

Antidepressants Assessed for Reducing Negative Symptoms of Schizophrenia

The Concept of Mental Illness, and Why the DSM Approach Is Wrong

Favorable Profile Data On MK-2214 for Treatment of Alzheimer Disease

Antidotes to Fear of Death